| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
NCDM-32B targets the KDM4 (JMJD2) subfamily of Jumonji C domain-containing histone lysine demethylases (JHDMs). It specifically inhibits KDM4C (JMJD2C), a histone demethylase that removes methyl groups from histone H3 at lysine 9 and lysine 36. By inhibiting KDM4 demethylase activity, NCDM-32B alters chromatin structure and gene expression patterns. This mechanism is relevant in cancer research, as KDM4 overexpression is associated with various malignancies.
|
|---|---|
| ln Vitro |
In vitro, NCDM-32B suppresses breast cancer cell viability and transformed phenotypes. The compound demonstrates potent and specific inhibition of KDM4 enzymes in biochemical assays. It has been evaluated for its enzyme-inhibitory activity and effect on human cancer cells. Detailed IC₅₀ values for KDM4 inhibition are available in the primary literature. The compound shows selectivity for the KDM4 subfamily over other histone demethylases.
|
| ln Vivo |
In vivo data for NCDM-32B are limited in publicly available sources. Based on its potent in vitro activity against KDM4 enzymes and cancer cell lines, the compound is expected to be useful for in vivo studies of KDM4 function in tumorigenesis. The compound's physicochemical properties suggest potential for in vivo administration. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
In vitro enzyme assays for NCDM-32B typically use recombinant KDM4 (JMJD2) enzymes and histone peptide substrates. The compound is dissolved in DMSO and diluted in assay buffer (50 mM HEPES, pH 7.5, 50 μM Fe(NH₄)₂(SO₄)₂, 1 mM α-ketoglutarate, 2 mM ascorbate). Reactions are initiated by adding substrate and incubated at 37°C for 30-60 minutes. Demethylation is detected by MALDI-TOF mass spectrometry or by measuring formaldehyde production using a fluorescence-based assay. IC₅₀ values are calculated from dose-response curves. Controls include DMSO vehicle and known KDM inhibitors.
|
| Cell Assay |
For cell-based assays, breast cancer cell lines (e.g., MCF-7, MDA-MB-231) are cultured in DMEM with 10% FBS. Cells are seeded in 96-well plates and treated with NCDM-32B at various concentrations (0.1-100 μM) for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo assays. Histone methylation levels (H3K9me3, H3K36me3) are measured by Western blotting. Gene expression changes are analyzed by RT-PCR. Cell proliferation and colony formation assays may also be performed. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NCDM-32B may be administered to rodents via intraperitoneal (IP) or intravenous (IV) injection. The compound is formulated in a suitable vehicle such as DMSO, PEG, or saline-based solutions. For tumor xenograft models, immunodeficient mice bearing breast cancer tumors are dosed at various regimens. Endpoints include tumor volume measurement, survival analysis, and biomarker assessment (histone methylation levels in tumor tissues). Blood and tissue samples are collected for pharmacokinetic and pharmacodynamic analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
NCDM-32B (MW 302.42, C₁₅H₃₀N₂O₄) is soluble in DMSO. The compound is a hydroxamate-based inhibitor with metal-chelating properties. Detailed pharmacokinetic parameters (bioavailability, half-life, clearance) are not extensively reported in publicly available sources. The compound is typically stored at -20°C. For in vivo use, it is formulated in suitable vehicles to ensure adequate exposure. Further ADME studies are needed to fully characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
Toxicology data for NCDM-32B are limited in publicly available sources. As a histone demethylase inhibitor, potential off-target effects on other Jumonji domain-containing proteins should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
NCDM-32B is a research-grade chemical probe for studying KDM4 histone demethylase function in cancer biology and epigenetics. Its primary applications include cancer research, epigenetics, and drug discovery. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves inhibition of KDM4-mediated histone demethylation, affecting gene expression programs involved in cancer cell proliferation and survival.
|
| Molecular Formula |
C15H30N2O4
|
|---|---|
| Molecular Weight |
302.415
|
| Exact Mass |
302.221
|
| CAS # |
1239468-48-4
|
| PubChem CID |
46901417
|
| Appearance |
White to light yellow solid powder
|
| LogP |
2.059
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
21
|
| Complexity |
295
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KDYRPQNFCURCQB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H30N2O4/c1-16(2)12-9-7-5-4-6-8-10-14(18)17(20)13-11-15(19)21-3/h20H,4-13H2,1-3H3
|
| Chemical Name |
methyl 3-[9-(dimethylamino)nonanoyl-hydroxyamino]propanoate
|
| Synonyms |
NCDM 32B; NCDM32B; NCDM-32B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~25 mg/mL (~82.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3067 mL | 16.5333 mL | 33.0666 mL | |
| 5 mM | 0.6613 mL | 3.3067 mL | 6.6133 mL | |
| 10 mM | 0.3307 mL | 1.6533 mL | 3.3067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
